LivDerm

 

LivDerm
E

CSCC Management Update: Why Is CCPDMA for High Risk CSCC Important? What Is the Efficacy of the New PD-1 Inhibitors?

By LivDerm FEATURING Emily Ruiz
February 18, 2021
0 Comments
Login to view comments. Click here to Login
2021 South Beach Symposium
02:58
LivDerm

Welcome Message & Highlights of the South Beach Symposium

Feat. M. Nestor
13:52
LivDerm

AMA Dermatology Coding Updates for 2021: What Are the Changes in Rei…

Feat. M. Kaufmann
09:39
LivDerm

Update on Biologic Therapies in Dermatology: Understanding the IL-17…

Feat. D. E. Cohen
10:15
LivDerm

Aesthetic & Clinical Approaches to Melasma: What are the Pre/Pos…

Feat. A. Mcmichael
10:16
LivDerm

Post-Inflammatory Hyperpigmentation in Skin of Color: How to Choose …

Feat. V. Callender
03:23
LivDerm

CSCC Management Update: Why Is CCPDMA for High Risk CSCC Important? …

Feat. E. Ruiz
06:17
LivDerm

Dermoscopy in Melanoma Screening: How to Differentiate Melanocytic L…

Feat. D. J. Goldberg
06:52
LivDerm

Innovations in Skin Cancer Diagnosis: Is Actinic Keratosis a Precurs…

Feat. C. Cockerell
05:30
LivDerm

Wound Care Management: Reducing Scarring Through Reducing Tension &a…

Feat. R. Kisner
05:03
LivDerm

Off Label Prescribing: Etanercept for SJS, Dupilumab for Prurigo Nod…

Feat. L. Stein Gold
08:59
LivDerm

Differences in Radiation Therapies for Skin Lesions: What Is the Eff…

Feat. M. Nestor
07:20
LivDerm

2021 LivDerm Update on Skin Cancer Diagnosis & Management: What …

Feat. D. Rigel